Aclarion Strengthens AI Platform for Chronic Back Pain Diagnosis with New U.S. Patent

Aclarion, Inc., a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled ‘System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.’ The patent covers the company’s machine learning platform for analyzing magnetic resonance spectroscopy (MRS) data to help physicians identify painful discs in the spine. This development strengthens Aclarion’s intellectual property portfolio to 64 issued and pending patents worldwide and protects the AI workflows in future versions of its Nociscan platform.

The Nociscan platform is a cloud-based system that converts complex MRS spectral data into clinically actionable insights. According to the company, the newly issued patent enhances scalability by protecting the use of AI to automate biomarker identification, accelerate report generation, and reduce manual quality reviews. Brent Ness, Chief Executive Officer of Aclarion, stated that the patent strengthens the foundation of the platform by protecting how AI transforms spectroscopy data into meaningful information for physicians. He emphasized that combining proprietary signal processing with machine learning builds a scalable and defensible approach to pain evaluation.

The patent specifically covers machine learning models that extract quantitative biomarkers from MRS data to generate standardized classifications for pain-related conditions. A key feature includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids or spectral artifacts. This capability aims to ensure consistent, reproducible outputs across different imaging systems and clinical sites, which is seen as a critical step toward broader clinical adoption. For more information on the company’s technology, visit https://www.aclarion.com.

Chronic low back pain represents a significant global healthcare challenge, affecting approximately 266 million people worldwide. Aclarion’s strategy focuses on building a differentiated, software-driven platform in this large market. Clinical data cited in the announcement indicates that when Nociscan is used alongside other diagnostic tools, there is up to a 97% surgical success rate when all Nociscan-positive discs are treated. The patent issuance is positioned to accelerate the company’s ability to scale and enhance gross margins by streamlining AI-driven workflows. For ongoing updates, the company maintains a newsroom at https://tinyurl.com/aconnewsroom.

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Aclarion Strengthens AI Platform for Chronic Back Pain Diagnosis with New U.S. Patent.

The post Aclarion Strengthens AI Platform for Chronic Back Pain Diagnosis with New U.S. Patent appeared first on citybuzz.